Procalcitonin Test for Differentiation of the Cause of Pneumonia
Usefulness of Procalcitonin Test to Differentiate the Cause of Pneumonia in Patients With Cancers
1 other identifier
observational
649
1 country
1
Brief Summary
The purpose of this study is to evaluate the usefulness of procalcitonin test for differentiation of the cause of pneumonia in patients with cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2014
CompletedFirst Submitted
Initial submission to the registry
November 17, 2017
CompletedFirst Posted
Study publicly available on registry
November 22, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2020
CompletedSeptember 25, 2020
September 1, 2020
6.5 years
November 17, 2017
September 24, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Procalcitonin level according to the cause of pneumonia in patients with cancer
bacterial pneumonia vs. radiation pneumonitis vs chemotherapy-induced pneumonitis
procalcitonin level is checked within 24hours after visiting hospital
Secondary Outcomes (2)
Influence of neutropenia on procalcitonin level in patients with baterial pneumonia
procalcitonin level is checked within 24hours after visiting hospital
procalcitonin level in patients with atypical pneumonia
procalcitonin level is checked within 24hours after visiting hospital
Study Arms (1)
procalcitonin pneumonia cohort
Patients who are suspected of acute pneumonia due to symptoms and imaging findings compatible with pneumonia can be enrolled in this cohort.
Interventions
All patients enrolled in this cohort undergo procalcitonin test in addition to basic microbiological test.
Eligibility Criteria
1. Patients who are suspected of acute pneumonia due to symptoms and imaging findings compatible with pneumonia can be enrolled in this cohort. * suspected symptom: cough, sputum, dyspnea or fever/chill * suspected image findings: consolidation or ground-glass opacity on chest radiograph or CT 2. All patients enrolled in this cohort undergo procalcitonin test in addition to basic microbiological test. * basic microbiological test: blood culture, sputum gram stain/culture, pneumococcal urinary antigen, legionella urinary antigen, mycoplasma antibody etc.
You may qualify if:
- Age greater than 18 years
- Patients who have symptoms and suspected imaging findings compatible with pneumonia
You may not qualify if:
- Patients who have been treated with antibiotics or steroid therapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Respiratory Clinic, National Cancer Center
Goyang-si, Gyeonggi-do, 410-769, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
HEE SEOK LEE, M.D.
National Cancer Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Pulmonologist
Study Record Dates
First Submitted
November 17, 2017
First Posted
November 22, 2017
Study Start
January 1, 2014
Primary Completion
June 30, 2020
Study Completion
June 30, 2020
Last Updated
September 25, 2020
Record last verified: 2020-09